1. Home
  2. Services
  3. Allergen Screening
  4. Cross-Reactivity Assessment

Cross-Reactivity Assessment

The Significance of Cross-Reactivity Assessment

Cross-reactivity assessment serves as a crucial method for both detection and analysis of molecular interactions among distinct molecules. Through cross-reactivity assessment researchers can determine if particular antibodies or reagents interact with non-target molecules which could compromise experimental result accuracy. Scientists enhance experiment precision through careful reagent selection based on their cross-reactivity assessments which boost both specificity and sensitivity.

Molecular interactions

Cross-reactivity assessment holds vital importance in both biomedical research and clinical diagnostic processes. Detection method reliability improves while the frequency of false positives and negatives decreases through cross-reactivity assessment which confirms experimental result accuracy. Early detection of diseases and monitoring treatment effectiveness together with drug research depend on this crucial factor.

  • Enhance Diagnostic Specificity: The identification of antibody cross-reactions with non-target antigens helps to minimize false positive results that occur due to misjudgments from structurally similar molecules in immunoassays.
  • Optimize Drug Development: The development of antibody drugs requires evaluating non-specific binding effects of candidate drugs to minimize toxicity risks.
  • Accelerate Vaccine Design: The process includes analysis of cross-reactive epitopes from pathogen antigens to generate data that assists with multivalent vaccine development.

Cross-Reactivity Assessment Services

Our range of superior testing and analysis services supports biomedical research clients and clinical diagnostics through cross-reactivity assessment. Here is a summary of our primary service offerings:

  1. High-Throughput Cross-Reactivity Screening: Supports parallel detection of 2000+ protein targets in a single experiment, covering all categories of biomarkers such as cytokines, chemokines, and immunoglobulins.
  2. Multi-Analyte Joint Detection: Simultaneously analyzes interaction profiles of antibodies with multiple types of targets, including transmembrane receptors, secreted proteins, and phosphorylated modified proteins.
  3. Customized Experimental Design: Provides target combination customization services based on drug development stage (lead compound optimization/preclinical research) or diagnostic reagent registration requirements.
  4. Data Analysis and Reporting: Offers in-depth analysis such as binding strength heatmaps, cross-reactivity rate matrices, and epitope similarity prediction, meeting declaration requirements under GLP regulations.
  5. Technical Method Development: Develops exclusive experimental protocols for novel biomarker detection based on near-infrared fluorescence labeling and silicone membrane technology.

Protein Array's Near-Infrared Microarray Protein Chip Technology Platform

Our protein array technology platform combines advanced technologies such as laser confocal microscopy, near-infrared fluorescence labeling, and specialized functional silicone membranes, specifically designed for cross-reactivity assessment. This platform features:

  • High-Throughput Detection: Capable of simultaneously detecting multiple target molecules, significantly improving experimental efficiency.
  • High Sensitivity: Specialized functional silicone membranes ensure high sensitivity and excellent biocompatibility.
  • Fully Automated Operation: Stable near-infrared fluorescence labeling signals, easy to clean, enabling fully automated operation.

Our platform for cross-reactivity assessment offers significant advantages over traditional methods. The laser confocal system ensures accuracy through its high sensitivity and broad linear range, delivering reliable results. Moreover, our platform provides enhanced cost-effectiveness, significantly reducing both expenses and detection time. With the capacity to screen over 2000 protein targets in a single experiment, the cost is only 30% of traditional ELISA. The system enables simultaneous analysis of antibody interactions with multiple target types such as cell surface receptors as well as secreted and modified proteins. Our testing system meets regulatory standards established by the FDA, EMA, and NMPA and provides Tissue Cross-Reactivity (TCR) data required for IND submissions.

Array Example

Panel DesignExample Antigen CombinationTarget ApplicationPossible Sample Preparation
Panel A: Multi-Species Ortholog Array- Orthologous proteins from different strains or species
e.g., Hemagglutinin (HA) from Influenza A H1, H3, H5, etc. or surface proteins from different bacterial serotypes.
- May include mutant or variant forms of each ortholog.		1. Identify breadth of antibody or T cell response across strains/species
2. Assess potential cross-protection or escape by variants		- In vitro: Supernatants from B or T cell cultures stimulated with a single strain's antigen (to see if cross-reactive with other strains)
- In vivo: Serum/plasma from immunized or infected animals/humans at multiple timepoints
Panel B: Related Pathogen/Antigen Set- Proteins from a family of pathogens (e.g., coronaviruses: SARS-CoV-2 spike, SARS-CoV-1 spike, MERS spike, HKU1 spike, etc.)
- Overlapping or domain-based arrays (e.g., RBD vs. full spike) if focusing on specific regions		1. Map cross-binding to multiple pathogens in a family
2. Evaluate pan-family antibody or T cell responses (e.g., pan-coronavirus)		- In vitro: Cell culture supernatants (antibody-secreting hybridomas, etc.)
- In vivo: Serum from convalescent or vaccinated subjects (humans/animals). If T cell-based, measure cytokines or proliferation with each antigen variant
Panel C: Off-Target / Self-Antigen- Array of known human self-proteins or potential off-target antigens
(e.g., common structural proteins, key enzymes, cytokines, or closely related but undesired targets)		1. Evaluate safety profile of mAbs or vaccine-induced antibodies
2. Screen for autoimmune reactivity or cross-binding to host molecules		- In vitro: Purified therapeutic antibody or serum tested on an array of self-proteins
- In vivo: Serum from immunized animals/humans to check if cross-reacting with self-proteins, especially in autoimmune-prone models

Application of Cross-Reactivity Assessment

  • Therapeutic Antibody Development: Screening for off-target binding risks of preclinical candidate molecules, optimizing antibody humanization design.
  • In Vitro Diagnostic Kit Validation: Assessment of cross-reactivity of diagnostic antibodies with similar biomarkers.
  • Allergen Component-Resolved Diagnostics: Recognition of cross-sensitizing epitopes between pollen, food and other allergens to support CRD diagnosis.
  • Vaccine Immunogenicity Evaluation: Quantifying the ability of vaccine-induced antibodies to cross-neutralize different pathogen variants.

Through advanced high-throughput protein interaction analysis and ultrasensitive cross-reactivity profiling our cross-reactivity assessment service boosts allergen research by substantially improving both accuracy and screening efficiency. The platform's multi-dimensional evaluation system systematically deciphers cross-reactive allergen networks, effectively distinguishing clinically relevant cross-sensitization from experimental artifacts. This technology enables the development of highly specific diagnostic reagents, optimizes allergen immunotherapy strategies, and provides robust technical support for precision diagnosis and risk management in food allergy, environmental allergy, and related fields.

Online Inquiry
Services